Ten years of progress in non-small cell lung cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 10, Issue 3, 2012, Pages 292-295

  Ettinger, David S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CRIZOTINIB; ERLOTINIB; GEFITINIB; GEMCITABINE; PACLITAXEL; PEMETREXED;

CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SCREENING; CANCER STAGING; HUMAN; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; NOTE; OVERALL SURVIVAL; PERSONALIZED MEDICINE; SYSTEMIC THERAPY; TREATMENT INDICATION; TREATMENT RESPONSE;

EID: 84858198984     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2012.0029     Document Type: Note

References (17)

1. Aberle DR, Adams AT, Berg CD, et al. Reduced lung cancer mortality with low dose computed tomographic screening. N Engl J Med 2011;365:395-409.
2. Fischer B, Lassen U, Mortensen J, et al. Preoperative staging of lung cancer with combined PET-CT. N Engl J Med 2009;361:32-39.
3. Medford AR, Bennett JA, Free CM, Agrawal S. Mediastinal staging procedures in lung cancer: EBUS, TBNA and mediastinoscopy. Curr Opin Pul Med 2009;15:334-342.
4. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals forthcoming (seventh edition of the TNM classification of malignant tumors). J Thorac Oncol 2007;2:706-714. (Pubitemid 47357522)
5. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol 2011;6:244-285.
6. Paul S, Altorki NK, Shubin S, et al. Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: a propensity-matched analysis from the STS database. J Thorac Cardiovasc Surg 2010;139:366-378.
7. Lo SS, Fakiris J, Chang EL, et al. Stereotactic body radiation therapy: a novel treatment modality. Nat Rev Clin Oncol 2010;7:44-54.
8. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone with bevacizumab for non-small cell lung cancer. N Engl J Med 2006:355:2542-2550. (Pubitemid 44917502)
9. Shepard FA, Pereira Rodrigues J, Tan EH, et al. Erlotinib in previously treated non-small cell lung cancer. New Engl J Med 2005;353:123-132.
10. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
11. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol, in press.
12. Keedy VL, Temin S, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011;29:2121-2127.
13. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcomes of patients with non-small cell lung cancer who harbor EML-4 ALK. J Clin Oncol 2009;27:4247-4253.
14. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011;12:1004-1012.
15. Arriagada R, Bergman B, Dunant A, et al. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med 2004;350:351-360. (Pubitemid 38101630)
16. Arriagada R, Dunant A, Pignon JP, et al. Long-term results of the International Adjuvant Lung Cancer Trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol 2010;28:35-42.
17. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432-1440.